Ingvild Kristiansen - Ambea AB Business Area Manager Stendi
| AMBEA Stock | SEK 99.60 2.40 2.35% |
Insider
Ingvild Kristiansen is Business Area Manager Stendi of Ambea AB
| Age | 50 |
| Phone | 46 8 57 87 00 00 |
| Web | https://www.ambea.se |
Ambea AB Management Efficiency
The company has return on total asset (ROA) of 0.0291 % which means that it generated a profit of $0.0291 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0795 %, meaning that it generated $0.0795 on every $100 dollars invested by stockholders. Ambea AB's management efficiency ratios could be used to measure how well Ambea AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter Madsen | Cantargia AB | N/A | |
| RGN MSc | BioInvent International AB | N/A | |
| Johanna Christensen | Cantargia AB | N/A | |
| Alex MD | Mendus AB | 73 | |
| Stefan MBA | BioInvent International AB | 60 | |
| Gustaf MSc | Isofol Medical AB | 55 | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| PerOlof Gunnesson | Mendus AB | 78 | |
| Bjrn Frendus | BioInvent International AB | 50 | |
| Jeroen MD | Mendus AB | 52 | |
| Ingrid Teige | BioInvent International AB | N/A | |
| Nina Valkama | Cantargia AB | N/A | |
| Thoas MD | Cantargia AB | 61 | |
| MD MBA | Mendus AB | 60 | |
| Dominique Tersago | Cantargia AB | 61 | |
| Roger Tell | Isofol Medical AB | N/A | |
| Roger MD | Isofol Medical AB | 58 | |
| Sylvie Ryckebusch | BioInvent International AB | N/A | |
| Marcuss | Cantargia AB | N/A | |
| Adnan Deronic | Cantargia AB | N/A | |
| Jenny Sundqvist | Isofol Medical AB | N/A | |
Management Performance
| Return On Equity | 0.0795 | |||
| Return On Asset | 0.0291 |
Ambea AB Leadership Team
Elected by the shareholders, the Ambea AB's board of directors comprises two types of representatives: Ambea AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ambea. The board's role is to monitor Ambea AB's management team and ensure that shareholders' interests are well served. Ambea AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ambea AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Malin Appelgren, Marketing Growth | ||
| Eva Domanders, Chief Executive Officer of Rent a Doctor, Nurse in Scandinavia AB and Careteam | ||
| Jan Wilken, Managing Altiden | ||
| Xenia Wenthzel, Director | ||
| Fredrik Gren, President and Chief Executive Officer, President and Chief Executive Officer of Vardaga AB and Nytida AB | ||
| Mikael Stohr, Independent Director | ||
| Lena Freiholtz, Director of Quality | ||
| Nanna Wedar, Communications and Marketing Director | ||
| Anders Borg, Director | ||
| Gunilla Rudebjer, Independent Director | ||
| Erik Sorensson, Head of Strategy & Acquisitions | ||
| Mark Jensen, CEO Pres | ||
| Magnus Sallstrom, Director, Employee Representative of Vision | ||
| Daniel Bjorklund, Director | ||
| Lena Hofsberger, Independent Chairman of the Board | ||
| Ulla Tansen, Business Area Manager, Vardaga | ||
| Magnus Akerhielm, Business Area Manager, Nytida | ||
| Daniel Warnholtz, Deputy Chief Executive Officer, Chief Financial Officer | ||
| Fredrik Malmborg, Managing Nytida | ||
| Maria GreenGadelius, Head of Quality & Sustainability | ||
| Miriam Toft, Business Area Manager, Altiden | ||
| Ingvild Kristiansen, Business Area Manager Stendi | ||
| Anders Westerholm, Head of Human Resources | ||
| Khasha Jeihouni, Director | ||
| Patricia Rodriguez, Director, Employee Representative for Kommunal | ||
| Haralampos Kalpakas, Director, Employee Representative for the Swedish Association of Health Professionals | ||
| Benno Eliasson, Chief Officer | ||
| Liselott Kilaas, Independent Director | ||
| Lars Gatenbeck, Independent Director |
Ambea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ambea AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0795 | |||
| Return On Asset | 0.0291 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 15.31 B | |||
| Shares Outstanding | 94.53 M | |||
| Shares Owned By Insiders | 29.08 % | |||
| Shares Owned By Institutions | 44.92 % | |||
| Price To Earning | 18.04 X | |||
| Price To Book | 0.97 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ambea Stock Analysis
When running Ambea AB's price analysis, check to measure Ambea AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ambea AB is operating at the current time. Most of Ambea AB's value examination focuses on studying past and present price action to predict the probability of Ambea AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ambea AB's price. Additionally, you may evaluate how the addition of Ambea AB to your portfolios can decrease your overall portfolio volatility.